AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients ...

AstraZeneca’s Fasenra (benralizumab) has been approved by the European Commission (EC) to treat eosinophilic granulomatosis ...

Fasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...

Can you do it? Can you ace these quiz questions about EGPA? They’re all derived from the current literature. At the end of the quiz, compare your score with those of your physician colleagues ...

has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated vasculitis that can result in damage to ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

and Nucala might be part of the initial treatment for nonsevere EGPA-type vasculitis (eosinophilic granulomatosis with polyangiitis vasculitis). Rituxan is also an important example. It might be used, ...

Fasenrarecommended for approval in the EU by CHMP for the treatment of eosinophilic granulomatosis with polyangiitis New indication supported by the MANDARA trial which showed nearly 60% of ...

Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...